New inhaler could reduce rescue treatments in hospitalized COPD patients

NCT ID NCT05292053

Completed Disease control Sponsor: Baylor Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a once-daily inhaler called Trelegy Ellipta in 80 adults hospitalized for a COPD flare-up. The goal was to see if it reduces the need for extra rescue breathing treatments and shortens hospital stays. Participants took the inhaler daily along with short-term steroids and were followed for 30 days after leaving the hospital.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol)
What this could lead to: If successful, this could show that a once-daily inhaler helps hospitalized COPD patients need fewer rescue treatments and have shorter hospital stays.
What could go wrong: This is a small, single-center study with only 80 participants, so results may not apply to all COPD patients. It is also open-label, meaning both patients and doctors knew the treatment, which can bias results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

Baylor Scott & White Health Research Institute

Dallas, Texas, 75246, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.